Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.46 |
| ▸ | STING1 | Q86WV6 | 8/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RAPGEF3 | O95398 | 2/20 | 0.45 |
| ▸ | GMNN | O75496 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | AHCY | P23526 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14946326 | 0.90 | STING1 (0.46) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL14946345 | 0.89 | STING1 (0.45) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL9964279 | 0.89 | STING1 (0.56) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL16271105 | 0.89 | STING1 (0.56) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL22983991 | 0.89 | STING1 (0.56) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL14946346 | 0.89 | STING1 (0.56) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL6895355 | 0.89 | STING1 (0.56) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL23813544 | 0.89 | STING1 (0.56) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL14946351 | 0.89 | STING1 (0.45) | STING1LMNAKMT2ARAPGEF3GMNN | |
| SCHEMBL29674371 | 0.89 | STING1 (0.56) | STING1LMNAKMT2ARAPGEF3GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-03-07 | — | — | US | disclosed |
| US-20210284679-A1 | ß-Modified Phosphoric Acid Compound Precursor, ß-Modified Phosphoric Acid Compound, Reaction Inhibitor and Medicine Containing the Same, and Method for Inhibiting Reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | PPM1A, PPM1G, PPM1F | EGFR 1445/4885ERBB2 1148/4885STING1 742/4885 |
| US-20210284679-A1 | ß-Modified Phosphoric Acid Compound Precursor, ß-Modified Phosphoric Acid Compound, Reaction Inhibitor and Medicine Containing the Same, and Method for Inhibiting Reaction | IRS1, PPM1A, PPM1G | EGFR 959/4885ERBB2 762/4885STING1 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.